WELCOME TO

Specialist Communications for Life Sciences
Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value and generate interest from commercial leads, investors and partners.

Our
Services
Focused on supporting life science companies to raise their profile, build corporate value, and generate interest, the services we provide include:
PR & Media
- Press releases
- Article writing and placement
- Media interviews
- Messaging
- Copy writing
- Social media
- Media training
- Events
Marketing
- Conference, event and trade show support
- Marketing literature
- Market research
- Campaign development
- Advertising
- Sponsorship
- Product launches
Design & Branding
- Website design and development
- Print collateral development
- Identity and logo creation
- Brand strategy
- Presentation development
- Video production
Investor Relations
- Business plan development
- Presentation development
- PR targeting the life science trade press read by investors

The
Team
An experienced senior team of specialists in life science communications, with expertise gained in-house and agency side, offering the flexibility to support both early-stage companies and large multinationals.
EVENTS
-
ELRIG Cell & Gene Therapy 2026
-
Investival Showcase USA
-
Bioprocessing Summit Europe
-
BIA – Advanced Therapies 2026 Congress
SPT Labtech to collaborate with Illumina to develop automated platform supporting genomics in decentralized healthcare settings
SPT Labtech to develop an automated sample preparation platform for Illumina to further optimize the efficiency and benefits of genomic workflows in decentralized healthcare settings Builds on success of existing [...]
SolasCure completes phase II clinical trial, demonstrating accelerated healing with Aurase Wound Gel
Aurase Wound Gel shows 22x faster debridement and 7x faster healing compared to standard of care in sloughy venous leg ulcers, supporting advancement to the next phase of development Data [...]
Centauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidate
Clinical candidate in ABX-01 programme, CTX-187, currently in development ahead of first in-human clinical trials to target Gram-negative bacterial infections Investment from the world’s largest venture capital fund focused exclusively [...]



















